Premium
Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: A single dose, 4 weeks, double‐blind, randomized, placebo controlled trial
Author(s) -
Rios Luis Augusto Seabra,
Panhoca Renato,
Mattos Demerval,
Srugi Miguel,
Bruschini Homero
Publication year - 2007
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.20300
Subject(s) - medicine , resiniferatoxin , placebo , urology , clinical endpoint , randomized controlled trial , urinary incontinence , clinical trial , overactive bladder , quality of life (healthcare) , surgery , nursing , receptor , alternative medicine , pathology , transient receptor potential channel , trpv1
Aims To assess the hypothesis that resiniferatoxin (RTX) can be useful in women with urgency incontinence and idiopathic detrusor overactivity (IDO), we conducted a prospective, double‐blind, randomized, placebo‐controlled, parallel trial comparing the effects of RTX and placebo. Materials and Methods Fifty‐eight patients were randomly assigned to receive a single intravesical dose of 100 ml of either RTX 50 nM or placebo. Safety and efficacy were evaluated over 4 weeks. The primary efficacy endpoints were voiding symptoms evaluated through the voiding diary. Secondary efficacy endpoint was urodynamic response. Quality of life was measured by the Kings' Health Questionnaire Results Although improving trends were seen in both groups after the instillations, no statistically significant differences were found between the groups in any of the clinical or urodynamic parameters. RTX instillations were well tolerated with few and self‐limited side‐effects. Conclusion A single 50 nM intravesical dose of RTX was not better than placebo for the treatment of women with IDO and urgency incontinence. Neurourol. Urodynam. 26:773–778, 2007. © 2007 Wiley‐Liss, Inc.